短时每日、夜间与常规家庭血液透析的患者与治疗生存率相似
该研究基于1996-2012年加拿大全国代表性家庭血液透析(HHD)队列,比较短时每日HHD、夜间HHD与常规HHD的患者及治疗生存率。多变量调整后,夜间HHD与短时每日HHD相比常规HHD在死亡或治疗失败复合终点上无显著差异,但夜间HHD在血管通路信息可及者中死亡删失治疗生存率有相对改善。
要点
- 夜间HHD与短时每日HHD相比常规HHD,死亡/治疗失败风险无显著降低。
- 夜间HHD在血管通路信息可及者中死亡删失治疗生存率相对改善(HR 0.75)。
- 常规HHD患者透析导管使用比例(43%)高于夜间HHD(32%)和短时每日HHD(31%)。
核心结论
- 在加拿大HHD队列中,短时每日和夜间HHD与常规HHD相比,患者/治疗生存率相似。
研究设计与样本
- 研究为全国代表性队列,纳入1996-2012年加拿大HHD患者,常规HHD 600例、夜间HHD 508例、短时每日HHD 202例。
主要发现
- 多变量调整后,夜间HHD对比常规HHD的死亡/治疗失败复合终点风险比0.83(95%CI 0.66-1.03),无统计学显著性。
- 短时每日HHD对比常规HHD的死亡/治疗失败复合终点风险比0.84(95%CI 0.63-1.12),无统计学显著性。
- 在血管通路信息可及者中,夜间HHD死亡删失治疗失败风险比0.75(95%CI 0.57-0.98)。
- 常规HHD患者透析导管使用率43%,夜间HHD为32%,短时每日HHD为31%。
临床怎么用
- 临床选择HHD模式时,短时每日或夜间HHD与常规HHD的患者/治疗生存率总体相似。
- 夜间HHD可能改善死亡删失治疗生存率,但需结合血管通路情况个体化评估。
局限性
- 研究为观察性队列,可能存在残余混杂。
- 血管通路信息仅部分患者可及,相关分析受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Home hemodialysis (HHD) has many benefits, but less is known about relative outcomes when comparing different home-based hemodialysis modalities. Here, we compare patient and treatment survival for patients receiving short daily HHD (2-3 hours/5 plus sessions per week), nocturnal HHD (6-8 hours/5 plus sessions per week) and conventional HHD (3-6 hours/2-4 sessions per week). A nationally representative cohort of Canadian HHD patients from 1996-2012 was studied. The primary outcome was death or treatment failure (defined as a permanent return to in-center hemodialysis or peritoneal dialysis) using an intention to treat analysis and death-censored treatment failure as a secondary outcome. The cohort consisted of 600, 508 and 202 patients receiving conventional, nocturnal, and short daily HHD, respectively. Conventional-HHD patients were more likely to use dialysis catheter access (43%) versus nocturnal or short daily HHD (32% and 31%, respectively). Although point estimates were in favor of both therapies, after multivariable adjustment for patient and center factors, there was no statistically significant reduction in the relative hazard for the death/treatment failure composite comparing nocturnal to conventional HHD (hazard ratio 0.83 [95% confidence interval 0.66-1.03]) or short daily to conventional HHD (0.84, 0.63-1.12). Among those with information on vascular access, patients receiving nocturnal HHD had a relative improvement in death-censored treatment survival (0.75, 0.57-0.98). Thus, in this national cohort of HHD patients, those receiving short daily and nocturnal HHD had similar patient/treatment survival compared with patients receiving conventional HHD.
引用
- Tennankore KK, Na Y, Wald R, et al. Short daily-, nocturnal- and conventional-home hemodialysis have similar patient and treatment survival. Kidney Int. 2017. PMID: 28844317. doi:10.1016/j.kint.2017.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。